TP53 mutation + KRAS mutation	Non Small Cell Lung Cancer	TP53 mutation + KRAS mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
TP53 mutation + KRAS mutation	Lung Adenocarcinoma	TP53 mutation + KRAS mutation	Lung Adenocarcinoma	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
TP53 mutation + KRAS mutation	Lung Adenocarcinoma	TP53 mutation + KRAS mutation	Lung Adenocarcinoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
TP53 mutation + KRAS mutation	Pancreatic Ductal Adenocarcinoma	TP53 mutation + KRAS mutation	Pancreatic Ductal Adenocarcinoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
TP53 mutation + KRAS mutation	Lung Adenocarcinoma	TP53 mutation + KRAS mutation	Lung Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
TP53 mutation + KRAS mutation	Colon Cancer	TP53 mutation + KRAS mutation	Colon Cancer	LY 2603618 Sensitive: D – Preclinical LY 2603618 Sensitive : D	LY 2603618 Sensitive: D – Preclinical LY 2603618 Sensitive : D

TP53 mutation + KRAS mutation

Associations